# Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

> **NCT00689390** · PHASE2,PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1954 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepacivirus

## Interventions

- **BIOLOGICAL:** Boceprevir
- **BIOLOGICAL:** Narlaprevir
- **BIOLOGICAL:** Peginterferon alfa-2b
- **DRUG:** Ribavirin
- **OTHER:** Blood/Plasma Collection

## Key facts

- **NCT ID:** NCT00689390
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02-20
- **Primary completion:** 2014-10-13
- **Final completion:** 2014-10-13
- **Target enrollment:** 1954 (ACTUAL)
- **Why stopped:** The study was terminated due to satisfaction of post-marketing commitments
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689390, "Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00689390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*